Evgen Pharma Share Chat (EVG)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Evgen Pharma	LSE:EVG	London	Ordinary Share	GB00BSVYN304	ORD 0.25P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+1.75p	+11.48%	17.00p	16.50p	17.50p	17.25p	15.25p	15.25p	328,114	12:41:53

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-3.0	-3.3	-	16.82

Evgen Pharma Share Discussion Threads

Showing 1326 to 1347 of 1350 messages

Chat Pages: 54 53 52 51 50 49 48 47 46 45 44 43 Older

Date	Subject	Author	Discuss
18/3/2019 11:11	mirako - not necessarily - the whole FDA accelerated approval pathway was set up to use surrogate endpoints eg biomarkers. I'm not sure how that position will change with Gottlieb moving, but I think accelerated approval is a very attractive option for a company like Evgen and they should be looking at it very closely.	supernumerary	Read Full Thread Reply
18/3/2019 10:43	The primary endpoint in this trial is a biomarker and the FDA will surely want evidence of clinical benefit.	mirako	Read Full Thread Reply
18/3/2019 10:39	It's clearly the correct thing to do, and as Nobby says, surprising that it wasn't always the case. I'm also curious about why they seem to be planning to make the current secondary endpoints into the primary endpoints in the next trial. If they get to the next phase it will be because they've succeeded in this one, so why change a winning formula?	supernumerary	Read Full Thread Reply
18/3/2019 08:51	Encouraging move this morning with about £20k shares bought. Could be an interesting week ahead of the results next week....	nobbygnome	Read Full Thread Reply
18/3/2019 07:59	Could really take off.	1hopefultrader	Read Full Thread Reply
18/3/2019 07:57	I guess it makes sense to announce all the SAH results together but I do wonder why they have only realised that now. Good the breast cancer results are out next week. Hopefully good results will mean that sulforaphane will proceed on to another trial!	nobbygnome	Read Full Thread Reply
18/3/2019 07:30	got to be in it to win it gl 90p	purple11	Read Full Thread Reply
18/3/2019 07:29	Evgen Pharma plc ("Evgen Pharma" or "the Company") Update on SFX-01 trial read-out dates Final read-out data from Phase II STEM trial expected next week Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the following update on the read-out of its two Phase II trials of SFX-01, the Company's lead development product. The final read-out of the STEM trial in metastatic breast cancer is expected to be announced early next week, in line with the Company's earlier guidance of Q1 2019. In the SAS trial of SFX-01 in subarachnoid haemorrhage, the Company is pleased to confirm that the treatment phase of the trial has now concluded with the last patient on the trial having received the final patient dose. Following advice from clinicians and statisticians, and in the light of commercial considerations, the Company has decided to announce the primary endpoints (safety, tolerability and measures of blood flow in the brain) and secondary endpoints (relating to cognitive function) at the same time, rather than announcing them separately as previously indicated. This approach fully protects the blinded integrity of the secondary endpoint data which continues to be collected post-dosing for six months from the initial haemorrhage. The SAS trial will therefore remain fully blinded until all of the secondary endpoint data has been collected. The final read-out continues to be expected in late summer 2019. Steve Franklin, CEO of Evgen Pharma, commented: "This is a hugely exciting time for Evgen as we build up to the read-out early next week of our Phase II clinical trial of SFX-01 in metastatic breast cancer. These results are expected to be followed in the late summer this year by the final read-out of our SAS Phase II trial of SFX-01 in subarachnoid haemorrhage. "Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time. By doing this, we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies. This approach will maximise the commercial value of the dataset from the SAS trial."	purple11	Read Full Thread Reply
13/3/2019 16:52	jonnybgood4 filtered. His message has been posted on all the biotech threads. And Firefox warned that the 4d pharma website (in English and Chinese) was insecure. DYOR etc.	stopstopgo	Read Full Thread Reply
12/3/2019 12:34	This wait seems even more frustrating as we already know the end points have been met.. or is it just my lack of patience showing through here?	l0ngterm	Read Full Thread Reply
06/3/2019 19:25	The ceo has said repeatedly let the science do the talking, not the PR team. So investors that look for news will get bored, chase something else etc. Others were expecting a spike or rise into the results. So not really surprised at where we are from a share price perspective.	l0ngterm	Read Full Thread Reply
06/3/2019 16:33	Only small amounts though - AIM is full of penny profit merchants	dave444	Read Full Thread Reply
06/3/2019 15:35	so close to gamechanging results and always constant selling.. so irritating.	purple11	Read Full Thread Reply
05/3/2019 18:00	I must learn how to spell. In my previous post I should of course have said sulforadex. I have now registered the word "sulphoradex", and will seek compensation from anybody on the BB using it.	stopstopgo	Read Full Thread Reply
05/3/2019 08:21	Oncology result in next 26 days!	dave444	Read Full Thread Reply
05/3/2019 07:19	Yes we could get a company coming in or at the very least grant funding through the various NHSE routes	dave444	Read Full Thread Reply
05/3/2019 07:15	Agree, seems to perform better than market leader. Will it lead to company being taken over I wonder?	ayl30	Read Full Thread Reply
05/3/2019 07:13	That is positive	dave444	Read Full Thread Reply
27/2/2019 17:14	If the results in the breast cancer trial are positive the next proposed step is a trial involving combination with Exemestane. I came across the following article; Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention hTTps://www.pnas.org/content/110/47/19065 As dave444 says we don't have long to wait. If they achieve 20% responders for the six months hopefully the market will view it as a success. However, the response at the interim readout was lukewarm at best.	pdt	Read Full Thread Reply
27/2/2019 13:46	We will have the result inside the next 32 days according to the RNS!	dave444	Read Full Thread Reply
25/2/2019 08:07	Timbo003, I'm a small investor, would like to have bought more but I have lots of plans while I'm still well 😀😀	blakeysangel	Read Full Thread Reply
25/2/2019 01:07	>>>Blakeysangel, good to hear you are still going strong and keeping so positive. Can you remind me, did you ever buy a few shares in Evgen?	timbo003	Read Full Thread Reply

Chat Pages: 54 53 52 51 50 49 48 47 46 45 44 43 Older

Your Recent History

LSE

EVG

Evgen Phar..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.